{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T16:34:24Z","timestamp":1778949264770,"version":"3.51.4"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To compare visual outcomes and recurrence rates between pro re nata (PRN), treat-and-extend and stop (TES), and treat-and-extend with chronic maintenance dosing (TEM) regimens of anti\u2013vascular endothelial growth factor (vascular endothelial growth factor) injections for myopic macular neovascularization (MNV) in multiethnic patients. <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This retrospective study included patients treated with PRN, TES, or TEM for myopic MNV using intravitreal bevacizumab or ranibizumab. The primary outcome measure was visual improvement at 12 months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Overall, 127 eyes of 117 patients (75 women and 42 men) were included. The mean follow-up duration was 37.9 months. The outcomes of PRN (47 eyes [37%]), TES (52 eyes [41%]), and TEM (28 eyes [22%]) were compared. All groups showed significant visual improvement at 12 months and at the final follow-up (all <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.05). Visual outcomes did not differ significantly between the three groups at 12 months and the final follow-up (all <jats:italic toggle=\"yes\">P<\/jats:italic> &gt; 0.05). However, the number of eyes with recurrences was significantly higher in the PRN group and significantly lower in the TEM group during the follow-up (38%, 21%, and 11% in the PRN, TES, and TEM groups, respectively; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.020). The PRN group received the fewest injections during follow-up (5.3, 10.9, and 19.9 injections in the PRN, TES, and TEM groups, respectively; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Comparing myopic MNV treatment regimens, anti-VEGF injections with PRN, TES, or TEM are effective for myopic MNV and have comparable visual outcomes. Because PRN provides favorable outcomes with fewer injections, it should be the first-line approach. However, a treat-and-extend approach with TES and TEM may be an option given individual patient factors.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000004256","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T04:54:42Z","timestamp":1724388882000},"page":"2057-2065","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["OUTCOMES OF PRO RE NATA VERSUS TREAT-AND-EXTEND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS FOR MYOPIC MACULAR NEOVASCULARIZATION IN MULTIETHNIC PATIENTS IN THE UNITED STATES"],"prefix":"10.1097","volume":"44","author":[{"given":"Shreya","family":"Swaminathan","sequence":"first","affiliation":[{"name":"Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raziyeh","family":"Mahmoudzadeh","sequence":"additional","affiliation":[{"name":"Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University, Philadelphia, Pennsylvania."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taku","family":"Wakabayashi","sequence":"additional","affiliation":[{"name":"Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University, Philadelphia, Pennsylvania."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mallory","family":"Bowers","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bita","family":"Momenaei","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M.","family":"Abishek","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirataollah","family":"Salabati","sequence":"additional","affiliation":[{"name":"Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University, Philadelphia, Pennsylvania."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Hsu","sequence":"additional","affiliation":[{"name":"Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University, Philadelphia, Pennsylvania."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James P.","family":"Dunn","sequence":"additional","affiliation":[{"name":"Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University, Philadelphia, Pennsylvania."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250605","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","article-title":"Global prevalence of myopia and high myopia and Temporal trends from 2000 through 2050","volume":"123","author":"Holden","year":"2016","journal-title":"Ophthalmology"},{"key":"R2-20250605","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ajo.2013.08.010","article-title":"Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an Evidence-based systematic review","volume":"157","author":"Wong","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"R3-20250605","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/APO.0000000000000234","article-title":"Epidemiology of pathologic myopia in Asia and worldwide","volume":"5","author":"Wong","year":"2016","journal-title":"Asia-pacific Journal Ophthalmology (Philadelphia, PA)"},{"key":"R4-20250605","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/S0161-6420(03)00461-5","article-title":"Myopic choroidal neovascularization: a 10-year follow-up","volume":"110","author":"Yoshida","year":"2003","journal-title":"Ophthalmology"},{"key":"R5-20250605","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/01.icu.0000120709.35941.e9","article-title":"Myopic choroidal neovascularization: natural course and treatment","volume":"15","author":"Ohno-Matsui","year":"2004","journal-title":"Curr Opin Ophthalmol"},{"key":"R6-20250605","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.oret.2022.06.009","article-title":"Long-term incidence and risk factors of macular fibrosis, macular atrophy, and macular Hole in eyes with myopic neovascularization","volume":"6","author":"Cicinelli","year":"2022","journal-title":"Ophthalmol Retina"},{"key":"R7-20250605","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/IAE.0000000000003675","article-title":"LONG-TERM treatment outcomes after bevacizumab therapy for macular neovascularization in white patients with high myopia","volume":"43","author":"Ravenstijn","year":"2023","journal-title":"Retina"},{"key":"R8-20250605","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1097\/IAE.0000000000002292","article-title":"Ranibizumab versus verteporfin photodynamic therapy in asian patients with myopic choroidal neovascularization: BRILLIANCE, a 12-month, randomized, double-masked study","volume":"39","author":"Chen","year":"2019","journal-title":"Retina"},{"key":"R9-20250605","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ophtha.2013.10.023","article-title":"RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia","volume":"121","author":"Wolf","year":"2014","journal-title":"Ophthalmology"},{"key":"R10-20250605","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/aos.13989","article-title":"Better visual outcome at 1 year with antivascular endothelial growth factor treatment according to treat-and-extend compared with pro re nata in eyes with neovascular age-related macular degeneration","volume":"97","author":"Aurell","year":"2019","journal-title":"Acta Ophthalmologica"},{"key":"R11-20250605","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s00417-019-04404-0","article-title":"Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study","volume":"257","author":"Augsburger","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R12-20250605","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1097\/IAE.0000000000000627","article-title":"Treat-and-extend regimens with anti-vegf agents in retinal diseases: a literature review and consensus recommendations","volume":"35","author":"Freund","year":"2015","journal-title":"RETINA"},{"key":"R13-20250605","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ajo.2018.05.026","article-title":"The treat-and-extend injection regimen versus alternate dosing strategies in age-related macular degeneration: a systematic review and meta-analysis","volume":"192","author":"Okada","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"R14-20250605","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1136\/bjophthalmol-2015-306987","article-title":"A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration","volume":"100","author":"Chin-Yee","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"R15-20250605","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1111\/aos.13031","article-title":"Treat and Extend versus Pro Re Nata regimens of ranibizumab in neovascular age-related macular degeneration: a comparative 12 Month study","volume":"95","author":"Hatz","year":"2017","journal-title":"Acta Ophthalmologica"},{"key":"R16-20250605","first-page":"CD011160","article-title":"Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia","volume":"12","author":"Zhu","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"R18-20250605","first-page":"19","article-title":"Ranibizumab in myopic choroidal neovascularization: a subgroup analysis by ethnicity, age, and ocular characteristics in RADIANCE","volume":"236","author":"Holz","year":"2016","journal-title":"OPH"},{"key":"R19-20250605","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ajo.2015.01.022","article-title":"International photographic classification and grading system for myopic maculopathy","volume":"159","author":"Ohno-Matsui","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"R20-20250605","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.ophtha.2015.01.025","article-title":"Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: the MYRROR study","volume":"122","author":"Ikuno","year":"2015","journal-title":"Ophthalmology"},{"key":"R21-20250605","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.preteyeres.2017.10.005","article-title":"Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia","volume":"63","author":"Ohno-Matsui","year":"2018","journal-title":"Prog Retin Eye Res"},{"key":"R22-20250605","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.ophtha.2017.04.028","article-title":"Myopic choroidal neovascularization: review, guidance, and consensus statement on management","volume":"124","author":"Cheung","year":"2017","journal-title":"Ophthalmology"},{"key":"R23-20250605","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1097\/IAE.0b013e318285cc24","article-title":"Ocular risk factors for recurrence of myopic choroidal neovascularization: long-term follow-up study","volume":"33","author":"Kang","year":"2013","journal-title":"RETINA"},{"key":"R24-20250605","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.ajo.2013.08.002","article-title":"Prognostic factors of eyes with na\u00efve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab","volume":"156","author":"Yang","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"R25-20250605","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.oret.2017.07.009","article-title":"Recurrence rate of choroidal neovascularization in neovascular age-related macular degeneration managed with a treat-extend-stop protocol","volume":"2","author":"Adrean","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"R27-20250605","doi-asserted-by":"crossref","first-page":"14768","DOI":"10.1038\/s41598-022-19062-2","article-title":"Recurrence of neovascular age-related macular degeneration after cessation of treat and extend regimen","volume":"12","author":"Hirata","year":"2022","journal-title":"Sci Rep"},{"key":"R28-20250605","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/j.ophtha.2015.06.053","article-title":"Factors associated with recurrence of age-related macular degeneration after anti-vascular endothelial growth factor treatment: a retrospective cohort study","volume":"122","author":"Kuroda","year":"2015","journal-title":"Ophthalmology"},{"key":"R29-20250605","doi-asserted-by":"crossref","first-page":"781421","DOI":"10.3389\/fmed.2021.781421","article-title":"Treat-and-Extend vs. Pro Re nata regimen of ranibizumab for diabetic macular edema\u2014a two-year matched comparative study","volume":"8","author":"Lai","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"R30-20250605","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/IAE.0000000000003673","article-title":"Risk factors of Vision loss and multiple recurrences in myopic macular neovascularization","volume":"43","author":"Cicinelli","year":"2023","journal-title":"RETINA"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004256","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T17:01:11Z","timestamp":1749142871000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004256","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]}}}